



**PENDING CLAIMS**

**RECEIVED**

**JUL 31 2002**

**CLEAN VERSION OF PENDING CLAIMS UNDER 37 C.F.R. 1.121(c)(1)**

**TECH CENTER 1600/2900**

1. An isolated polypeptide consisting of the amino acid sequence as set forth in SEQ ID NO: 7.

6. A fusion polypeptide consisting of the polypeptide of any of Claims 1, 3, or 5 fused to a heterologous amino acid sequence.

7. The fusion polypeptide of Claim 6 wherein the heterologous amino acid sequence is an IgG constant domain or fragment thereof.

8. A composition comprising the polypeptide of Claim 1 and a pharmaceutically acceptable formulation agent.

9. The composition of Claim 8 wherein the pharmaceutically acceptable formulation agent is a carrier, adjuvant, solubilizer, stabilizer, or anti-oxidant.

11. The polypeptide of Claim 1 which is covalently modified with a water-soluble polymer.

12. The polypeptide of Claim 11 wherein the water-soluble polymer is selected from the group consisting of polyethylene glycol, monomethoxy-polyethylene glycol, dextran, cellulose, poly-(N-vinyl pyrrolidone) polyethylene glycol, propylene glycol homopolymers, polypropylene oxide/ethylene oxide co-polymers, polyoxyethylated polyols, and polyvinyl alcohol.

13. The polypeptide of Claim 11 wherein the water-soluble polymer is selected from the group consisting of polyethylene glycol and dextran.